Laura Swartz

Recent Posts

NEW RESEARCH: 52-page Report Available on Aeterna Zentaris Inc. (AEZS-NASDAQ)

Posted by Laura Swartz

April 21, 2015 at 4:11 PM

Crystal Research Associates has issued a comprehensive, 52-page Executive Informational Overview (EIO) on Aeterna Zentaris Inc. (AEZS-NASDAQ; AEZ-TSX). 

Company Snapshot

Aeterna Zentaris (“Aeterna” or “the Company”) is transitioning into a specialty biopharmaceutical company in oncology, endocrinology, and women’s health. With a focus on establishing revenues and profitability while optimizing resources to reduce its burn rate, the Company co-promotes a non-patch estrogen replacement therapy, EstroGel®, in specific U.S. markets with partner, Ascend Therapeutics (“Ascend”). As well, Aeterna holds a pipeline of candidates in varying stages of development and is working to acquire, in-license, or co-promote other commercial compounds.

Read More

Topics: AEZS

NEW RESEARCH: 56-page Executive Informational Overview Released on Juhl Energy, Inc.

Posted by Laura Swartz

April 14, 2015 at 8:00 AM

Crystal Research Associates has issued a 56-page Executive Informational Overview® (EIO) on Juhl Energy, Inc. (JUHL-OTC). Juhl Energy and its wholly-owned operating subsidiaries are engaged in the development and provision of competitive, clean energy solutions across the U.S. and Canada, with a focus on wind, solar, biomass, and natural gas systems. The Company’s activities can be categorized in three areas: (1) wind farm ownership; (2) development and system sales; and (3) engineering and field services. In the past 15 years, Juhl Energy has completed 23 wind farms that generate a total of 240 megawatts (MW) of wind power. Another 20 projects are in development, including a wind farm at Indiana’s Purdue Energy Park and New York’s first community wind project, the Black Oak Wind Project. In addition, the Company has an ownership stake in multiple wind farms (approximately 25 MW) and provides operation management and maintenance services for renewable energy assets.

Read More

Topics: JUHL

Boston Therapeutics Announces Q4 and FY 2014 Financial Results and Corporate Update

Posted by Laura Swartz

March 31, 2015 at 2:19 PM

MANCHESTER, NH -- (Marketwired) -- 03/27/15 -- Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, has reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update.

Read More

Topics: BTHE

Boston Therapeutics Expands Sugardown® License to Japan; Chinese Trial to Start

Posted by Laura Swartz

March 17, 2015 at 12:11 PM

Boston Therapeutics and Advance Pharmaceutical Company (APC) announced today the expansion of their sugardown® licensing agreement to Japan, a move that increases the number of Asian countries covered by the agreement to 16. Advance Pharmaceutical further reiterated its commitment to collaborate with Boston Therapeutics for funding of clinical trials for sugardown®. Upcoming product development trials are expected to include a pre-diabetes study of sugardown® at the Chinese University of Hong Kong and a U.S. Phase II study at the Joslin Diabetes Center in Boston for Boston Therapeutics’ BTI-320 candidate (a new generation of alpha glucosidase inhibitor that is designed to reduce post-meal elevation of blood glucose).

Read More

Topics: BTHE

Amarantus BioScience Publishes Positive Parkinson's Phase 2a Data in Brain Journal

Posted by Laura Swartz

February 11, 2015 at 9:00 AM

Yesterday, biotechnology company Amarantus BioScience Holdings, Inc. ( AMBS-OTC) announced that the clinical trial results of its Phase 2a study of eltoprazine to treat Parkinson’s disease levodopa-induced dyskinesias (PD-LID) would be published in an upcoming print edition of Brain: A Journal of Neurology.
Read More

Topics: Amarantus

Pressure BioSciences Announces First Sale of Barozyme™ HT48 and Accelerated Marketing

Posted by Laura Swartz

February 10, 2015 at 11:46 AM

This morning, laboratory instrumentation company Pressure BioSciences, Inc. (PBIO-OTC) announced that it had received the first purchase order for one of its newest products, the Barozyme™ HT48 High-throughput System, and had the potential for a second order for the same product. The possible second purchase could come from an existing European customer that has requested a quote.
 
About the Barozyme™ HT48

Read More

Topics: Pressure BioSciences

Boston Therapeutics Measures the Impact of sugardown® Taken Before Sodas

Posted by Laura Swartz

January 20, 2015 at 11:18 AM

On Tuesday, January 20, 2015, Boston Therapeutics, Inc. (BTHE-OTC) released additional trial results from its Sydney University study that showed consumption of sugardown® tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose, and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown® tablets were found to reduce glucose and fructose levels by up to a total of 20% and insulin levels by up to 14%. Four sugardown® tablets were found to reduce total glucose and fructose levels by up to 28% and insulin levels by up to 18%. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier in January that there was an average reduction in glycemic index (GI) of approximately 10% following soft drink consumption with two sugardown® tablets.

Study Details and Discussion

Read More

Topics: BTHE

Amarantus Acquires Specialized Neuro-Diagnostics Company, DioGenix, Inc.

Posted by Laura Swartz

January 12, 2015 at 12:24 PM

  • Lead Product MSPrecise(R): Clinically Validated, First-In-Class Next-Generation Sequencing (NGS) Assay that Identifies Multiple Sclerosis (MS) at First Clinical Presentation
  • Recent Prospective Study at 13 U.S. Centers of MS Excellence Demonstrated the Significant Diagnostic Accuracy of MSPrecise
  • Platform for Comprehensive Molecular Profiling of Immune-mediated Neurodegenerative Diseases
Read More

Topics: Amarantus

New Topical Cannabis Cream, TopiCanna, Hits the Market

Posted by Laura Swartz

December 16, 2014 at 10:30 AM

This week, diversified life sciences company Tauriga Sciences, Inc. (TAUG-OTC) launched its first proprietary topical medicinal cannabis cream branded as TopiCanna and provided a corporate update. Highlights of the news are described below, and the complete press release is available here.

Read More

Topics: Tauriga

New Video Clip: Jeff Kraws Talks Antibiotic Resistance Forecasts and Impacts

Posted by Laura Swartz

December 15, 2014 at 12:51 PM

In the wake of a new report from the British government stating that antibiotic-resistant infections could kill 10 million people each year by the year 2050, senior pharmaceutical analyst Jeff Kraws of Crystal Research Associates sits down with host Akhtar Khan of Arise Xchange to discuss the report's projections and impacts of increasing drug resistance on the pharmaceutical industry and on consumers.

Read More

Topics: Crystal Research Associates

Chewable Pill to Help Treat Type 2 Diabetes Receives IND Approval

Posted by Laura Swartz

December 10, 2014 at 9:19 AM

This morning, pharmaceutical company Boston Therapeutics, Inc. (BTHE-OTC) reported that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) filing for BTI-320, a new generation of alpha glucosidase inhibitor that is designed to reduce post-meal elevation of blood glucose. BTI-320 is expected to be taken before meals and works in the gastrointestinal tract to block the enzymes that break down and release carbohydrates into the bloodstream as glucose. With an approved IND, the company plans to start a major clinical study of BTI-320 in the first quarter 2015, as detailed in Boston Therapeutics' press release below.

Read More

Topics: BTHE

NEW RESEARCH: Quarterly Update Available on Truett-Hurst (THST)

Posted by Laura Swartz

December 4, 2014 at 11:18 AM

Crystal Research Associates has released a 16-page Quarterly Update on Truett-Hurst, Inc. (THST-NASDAQ). Truett-Hurst is a wine sales, marketing, and production company specializing in $7.00 to $50.00 per bottle wines. The company is known for its quality and packaging innovations. Based in the Dry Creek and Russian River Valleys of Sonoma County, California, its product line includes over 30 wine brands. Truett-Hurst’s largest business segment is its retail exclusive label partnerships with major retailers, including Trader Joe’s, Safeway, and Total Wine & More. For retail exclusive label sales, the company combines its competitive grape sourcing and skill in wine making and production with its understanding of consumer trends and unique approach to creating wine bottles that stand out on the retail shelf. These wines are sold exclusively by a retailer (e.g., Safeway) under a retail exclusive brand. The company also produces four of its own wine brands, which are sold through U.S. and Canadian distributors. Truett-Hurst further capitalizes on several direct-to-consumer sales channels, such as tasting rooms at its California wineries, wine clubs, and online sales through The Wine Spies, LLC (www.thewinespies.com) (an Internet wine retailer specializing in limited offerings and other online offerings as well as flash sales).

Read More

Topics: Truett-Hurst

Amarantus Announces Major Potential Acquisition and 2014 LymPro Test® Launch

Posted by Laura Swartz

November 20, 2014 at 10:52 AM

Since the publication of our Executive Informational Overview® (EIO) on Amarantus BioScience Holdings, Inc. (AMBS-OTC) in early September 2014, the company has advanced development of each of its three lead programs. Amarantus published data from a 72-patient study of the LymPro Test® demonstrating the test’s accuracy at identifying patients with moderate-to-severe Alzheimer's Disease versus healthy controls, completed enrollment of an expanded 140-patient study of LymPro for which results are expected by mid-December 2014, submitted its Phase 2b trial design for Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia to the FDA for review and written feedback, and submitted an Orphan Drug application to the FDA for MANF in retinitis pigmentosa, a degenerative eye disease. By the end of 2014, Amarantus expects to be able to launch the LymPro Test® for research markets (Investigational Use Only), and believes it can use the data from the expanded 140-patient LymPro study in support of a broader product launch in 2015.

Read More

Topics: Amarantus

Pressure BioSciences Reports a YTD Sales Increase of 45%

Posted by Laura Swartz

November 18, 2014 at 10:15 AM

Pressure BioSciences, Inc. (PBIO-OTC) has reported its financial results for the third quarter 2014 and year-to-date period ended September 30th. Highlights of these results are an increase in products and services revenue of 14% for the third quarter, while operating loss continues to narrow. Year to date, the company reported products and services revenue up 45% and sales of consumables up 48%, which almost entirely offset the loss in grant revenue.

Read More

Topics: Pressure BioSciences

New Study Measures Impact of OTC Supplement to Reduce Glucose and Insulin After Drinking Soda

Posted by Laura Swartz

November 17, 2014 at 11:37 AM

Following Boston Therapeutics' (BTHE-OTC) early November announcement for the launch of sugardown® branding in North America, the pharmaceutical company today informed investors that it has commenced a clinical study for sugardown® at Sydney University. The sugardown® dietary supplement is already available over-the-counter to help individuals maintain healthy blood sugar levels. The current clinical trial is intended to further researchers' understanding of the mechanisms and effect of sugardown®, which has already been demonstrated to be beneficial when taken in conjunction with solid food. The newest study at Sydney University's Glycemic Index Research Service (SUGiRS) will be the first to evaluate sugardown®'s effectiveness with sugary beverages, and seeks to measure sugardown®'s ability to reduce glucose and insulin levels following consumption of sugary drinks like sodas.

Read More

Topics: BTHE

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic